Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Ovarian Endometrioid Adenocarcinoma
Mayo Clinicgene_therapyPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 81/ 100
Competitive context
43 Active assets in the Ovarian Endometrioid Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin National Cancer Institute (NCI) | Phase 3 | BBB |
Olaparib University of Colorado, Denver | Phase 3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 3 | BB |
Cyclophosphamide Roswell Park Cancer Institute | Phase 2 | BB |
Pembrolizumab Roswell Park Cancer Institute | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →